Publicaciones en las que colabora con Bonaventura Casanova Estruch (11)

2020

  1. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

    Frontiers in Neurology, Vol. 11

2017

  1. Sodium intake and multiple sclerosis activity and progression in BENEFIT

    Annals of Neurology, Vol. 82, Núm. 1, pp. 20-29

2015

  1. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

    Clinica Chimica Acta, Vol. 438, pp. 67-69

  2. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e147

  3. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

    Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457

  4. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 61, Núm. 6, pp. 271-283

  5. Review of the novelties from the 2014 ectrims-actrims joint congress, presented at the 7th post-ectrims meeting (i)

    Revista de Neurologia, Vol. 61, Núm. 5, pp. 215-224

2014

  1. Biomarkers in multiple sclerosis: An update for 2014

    Revista de Neurologia, Vol. 58, Núm. 12, pp. 553-570

  2. Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis

    Annals of Neurology, Vol. 76, Núm. 2, pp. 231-240

2011

  1. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice

    Journal of Immunological Methods, Vol. 371, Núm. 1-2, pp. 170-173

2009

  1. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

    Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228